Keywords: USA, Market, Human Genime, GlaxoSmithKline, Benlysta, Roche, Biogen, Rituxan, MabThera, Decision Resources
Rheumatologists’ uptake of Benlysta will not lead to decline in patient share for immunosuppressant/cytotoxics or for Rituxan through 2013
Article | 24 February 2011
The uptake of Human Genome Sciences/GlaxoSmithKline’s emerging B-cell inhibitor Benlysta (belimumab), over the next two years for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
